CEL-SCI (NYSEAMERICAN:CVM) Stock Price Up 5.6%

Shares of CEL-SCI Co. (NYSEAMERICAN:CVM) rose 5.6% during mid-day trading on Friday . The company traded as high as $8.07 and last traded at $8.07, approximately 736,224 shares changed hands during trading. An increase of 5% from the average daily volume of 699,654 shares. The stock had previously closed at $7.64.

CEL-SCI (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.27). The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.10 million.

In other CEL-SCI news, SVP John Cipriano sold 8,000 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $7.03, for a total transaction of $56,240.00. Following the transaction, the senior vice president now owns 91,108 shares in the company, valued at $640,489.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

A number of hedge funds have recently modified their holdings of CVM. Captrust Financial Advisors purchased a new position in shares of CEL-SCI in the second quarter valued at approximately $25,000. Steward Partners Investment Advisory LLC purchased a new position in shares of CEL-SCI in the second quarter valued at approximately $25,000. Endurance Wealth Management Inc. purchased a new position in shares of CEL-SCI in the second quarter valued at approximately $29,000. JPMorgan Chase & Co. purchased a new position in shares of CEL-SCI in the second quarter valued at approximately $57,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of CEL-SCI in the first quarter valued at approximately $42,000.

CEL-SCI Company Profile (NYSEAMERICAN:CVM)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Featured Story: Why Dividend Stocks May Be Right for You

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.